Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 12, 2026 · Filed Nov 13, 2026
Perspective Therapeutics's Chief Medical Officer paid $30K out of pocket for Perspective Therapeutics shares. 1 other person at Perspective Therapeutics bought some too, in the same month. Shares held went up 24% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$29,565
Shares × reported transaction price
$25K–$100K
+24.4%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 0 months
Confirmed open-market purchases by the same insider in the available history
Yes
Compared with 1 earlier confirmed purchase
2 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 1.7% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2025 ($1.76M)
An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-16. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement
3 days after results of Nov 9, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $0.8424 on Nov 12, 2026, 7% above its 52-week low and 85% below its high, after a 69% drop over the previous 30 trading days
52-week range $0.7864 (Nov 10, 2026) to $5.65 (Feb 19, 2026), 1% of the way up, from 250 adjusted closes. 30 trading days earlier: $2.72 on Oct 1, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Insider buying
First insider buy since Mar 2025Traded Nov 11 · filed 2 days later
Perspective Therapeutics's Chief Medical Officer paid $5K out of pocket for Perspective Therapeutics shares. 1 other person at Perspective Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Insider buying
First insider buy since Mar 2025Traded Nov 11 · filed 1 day later
The CEO of Perspective Therapeutics paid $38K out of pocket for Perspective Therapeutics shares. 1 other person at Perspective Therapeutics bought some too, in the same month. It was the first purchase in 20 months.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
